3.Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma.
Bo NI ; Yiqing YIN ; Zekun LI ; Junjin WANG ; Xiuchao WANG ; Kaiyuan WANG
Neuroscience Bulletin 2023;39(11):1717-1731
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy, characterized by late diagnosis, aggressive growth, and therapy resistance, leading to a poor overall prognosis. Emerging evidence shows that the peripheral nerve is an important non-tumor component in the tumor microenvironment that regulates tumor growth and immune escape. The crosstalk between the neuronal system and PDAC has become a hot research topic that may provide novel mechanisms underlying tumor progression and further uncover promising therapeutic targets. In this review, we highlight the mechanisms of perineural invasion and the role of various types of tumor innervation in the progression of PDAC, summarize the potential signaling pathways modulating the neuronal-cancer interaction, and discuss the current and future therapeutic possibilities for this condition.
Humans
;
Carcinoma, Pancreatic Ductal/pathology*
;
Pancreatic Neoplasms/therapy*
;
Signal Transduction
;
Peripheral Nerves/metabolism*
;
Tumor Microenvironment
4.Clinicopathological Features of Intraductal Pancreatic Neuroendocrine Tumors.
Xiao-Yan CHANG ; Cong-Wei JIA ; Yun-Xiao MENG ; Jie CHEN
Acta Academiae Medicinae Sinicae 2016;38(5):568-573
Objective To evaluate the clinical and pathologic characteristics of intraductal pancreatic neuroendocrine tumors (PanNETs). Methods Four cases of intraductal PanNETs were studied by light microscopy and immunohistochemistry with the analysis of morphologic features and review of relevant literatures. Results Two female patients and two male patients aged 41- 58 years were enrolled in this study. The chief complaint was abdominal pain in two patients,vomiting in one patient,and jaundice in the last patient. Imaging examination showed intraductal neoplasm with diagnosis as intraductal papillary mucinous neoplasm (IPMN) in case 1; space-occupying lesions were found in the head of pancreas in the other three cases with pancreatic ductal ectasia and distal pancreatic atrophy. Grossly the masses were located in pancreatic main duct and invaded into surrounding pancreatic parachyma. Microscopically the tumors arranged with solid pattern,with some trabecular structures in the last two cases. Small duct and ductules were seen in intraductal PanNETs. The immunohistochemical expression showed that SYN and CgA were positive in neoplastic cells and negative in small duct and ductules.Conclusions Intraductal PanNETs are rare conditions. The clinical symptoms and imaging findings are similar to IPMN or pancreatic carcinoma. The tumors are located within pancreatic duct partly and can invade the pancreatic parenchyma. Microscopically the neuroendocrine tumors mix with small duct and forms ductulo-insular structure,which should be differentiated with mixed ductal endocrine carcinoma. The grade and prognosis are similar to those of classical neuroendocrine tumors.
Aged
;
Carcinoma, Pancreatic Ductal
;
pathology
;
Female
;
Humans
;
Immunohistochemistry
;
Male
;
Middle Aged
;
Neuroendocrine Tumors
;
pathology
;
Pancreas
;
pathology
;
Pancreatic Neoplasms
;
pathology
;
Prognosis
5.Focus on the conceptual change of pancreatic neoplasms.
Chinese Journal of Pathology 2013;42(6):361-362
6.Pancreatic Metastasis from Invasive Ductal Carcinoma of the Breast.
Jin Hee NOH ; Su Jin KOH ; Hye Jeong CHOI ; Hee Jeong JEON ; Jae Sung AHN ; Yunsuk CHOI ; Young Joo MIN
Korean Journal of Medicine 2017;92(3):308-311
Pancreatic metastases from primary breast cancer are very rare. We report a case of pancreatic metastasis from invasive ductal carcinoma 13 years after the initial diagnosis of breast cancer. When the pancreatic mass was discovered, it was believed to be a primary pancreatic cancer due to the long interval from the initial diagnosis of breast cancer to metastasis. However, it was confirmed as metastatic breast cancer based on the pathology after surgical removal. Follow-up imaging has shown no recurrence.
Breast Neoplasms
;
Breast*
;
Carcinoma, Ductal*
;
Diagnosis
;
Follow-Up Studies
;
Neoplasm Metastasis*
;
Pancreatic Neoplasms
;
Pathology
;
Recurrence
7.Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Jinbo SHI ; Xiawei LI ; Yulian WU
Journal of Zhejiang University. Medical sciences 2021;50(3):375-382
To investigate whether chemotherapy could prolong the postoperative survival time in patients with early stages pancreatic ductal adenocarcinoma (PDAC). A total of 5280 stage ⅠA -ⅡB PDAC patients diagnosed from 2010 to 2015 were selected from surveillance,epidemiology,and end results (SEER) database. Propensity score matching (PSM) analysis was adopted to reduce the baseline differences between the groups. Univariate survival analysis was conducted with the Kaplan-Meier method. Multivariate survival analysis was performed with the Cox proportional hazards model. Univariate and multivariate survival analyses showed that age, differentiation, stage, chemotherapy were independent risk factors for the survival of PDAC patients. After PSM, it is found that adjuvant chemotherapy could prolong the median overall survival time (mOS) for stage ⅠB, ⅡA and ⅡB patients. However, for stage ⅠA patients, there were no significant differences in 3-year survival rate and mOS between patients with chemotherapy (=283) and without chemotherapy (=229) (57.4% vs 55.6%, vs all >0.05). Further analyses show that among 101 patients with well differentiated PDAC and 294 patients with moderately differentiated PDAC, there were no significant differences in survival rate and mOS between patients with and without chemotherapy (all >0.05). Among 117 patients with low-differentiated + undifferentiated PDAC, 3-year survival rate and mOS in patients with chemotherapy were significantly better than those without chemotherapy (48.5% vs 34.1%, vs all <0.05). Chemotherapy regimen used currently is not beneficial for patients with moderately and well differentiated stage ⅠA PDAC, but it is an independent prognostic factor for low-differentiated + undifferentiated PDAC patients.
Adenocarcinoma/pathology*
;
Carcinoma, Pancreatic Ductal/surgery*
;
Chemotherapy, Adjuvant
;
Humans
;
Neoplasm Staging
;
Pancreatic Neoplasms/drug therapy*
;
Prognosis
;
Propensity Score
8.Mutant K-ras gene in pathogenesis of pancreatic ductal adenocarcinoma.
Chinese Journal of Pathology 2012;41(1):62-65
Animals
;
Carcinoma, Pancreatic Ductal
;
genetics
;
pathology
;
Genes, ras
;
genetics
;
Humans
;
Metaplasia
;
MicroRNAs
;
genetics
;
Mutation
;
Pancreatic Ducts
;
pathology
;
Pancreatic Neoplasms
;
genetics
;
pathology
;
Pancreatitis
;
genetics
;
Signal Transduction
9.Introduction of 2010 WHO classification of pancreatic tumors.
Chinese Journal of Pathology 2013;42(6):423-425
Carcinoma, Pancreatic Ductal
;
classification
;
pathology
;
Cystadenocarcinoma
;
classification
;
pathology
;
Cystadenoma
;
classification
;
pathology
;
Humans
;
Neuroendocrine Tumors
;
classification
;
pathology
;
Pancreatic Neoplasms
;
classification
;
pathology
;
Precancerous Conditions
;
classification
;
pathology
;
World Health Organization
10.A clinical study about applying different R1 criteria to evaluate pancreatic head ductal adenocarcinoma specimens.
Ying PENG ; Dianrong XIU ; Bin JIANG ; Zhaolai MA ; Chunhui YUAN ; Jing SU ; Xueying SHI ; Lei LI ; Ming TAO
Chinese Journal of Surgery 2014;52(11):834-838
OBJECTIVETo analyze the R1 rate of the pancreatic head carcinoma resection specimens which delt with a unified protocol by two different R1 criteria.
METHODSBetween November 2011 and October 2013, a unified pathological protocol was prospectively used to handle 70 consecutive pancreatioduodenectomy specimens for pancreatic ductal adenocarcinoma. Apart from the pancreatic transection margin, the bile duct and stomach/jejunum margins, different colors were used to stain the anterior surface, the superior mesenteric vein (SMV) groove margin, the superior mesenteric artery (SMA) margin, and the posterior surface. Axial slicing technique was used to dissect the pancreatioduodenectomy specimens.
RESULTSAmong the 70 patients, 3, 30 and 37 patients were classified as well, moderately and poorly differentiated respectively;7, 15 and 48 patients were classified as pT1, pT2 and pT3 respectively.Forty patients (57.1%) had metastases in regional lymph nodes (pN1) , and 16 patients (22.9%) had metastases in para-aortic nodes.Resection of the portal vein and/or the superior mesenteric vein was performed in 13 patients (18.6%) .When applying the UICC criteria, 26 cancer resections were classified R1 (37.1%) , 33 margins were turned out to be R1. The SMV groove margin and SMA margin were infiltrated in 13 specimens (13/33, 39.4%) respectively.When applying the Royal College of Pathologist's criteria, 39 cancer resections were classified R1 (55.7%) , 51 margins were turned out to be R1. The SMV groove margin and SMA margin were infiltrated in 18 (18/51, 35.3%) and 19 (19/51, 37.3%) specimen respectively.Until April 2014, the median follow-up was 18(range 6-42) months.
CONCLUSIONSApplying the unified protocol for pancreatic head ductal adenocarcinoma specimens results in an significant R1 rate of the resection margins, and the R1 rate is related to the R1 criterion. The SMV groove margin and SMA margin are the two most frequent sites of R1.
Adenocarcinoma ; pathology ; Carcinoma, Pancreatic Ductal ; pathology ; Diagnostic Techniques and Procedures ; Humans ; Lymph Nodes ; pathology ; Mesenteric Artery, Superior ; surgery ; Pancreas ; pathology ; Pancreatic Neoplasms ; pathology ; Portal Vein ; surgery